Inhibitor Therapeutics, Inc. (INTI)

Import this data to Google Sheets with:

=jivedata("INTI","financials")

Full statements spill as a table. For one cell: =jivedata("INTI","Revenue") or =jivedata("INTI","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Inhibitor Therapeutics, Inc.

INTI • CIK 0001042418

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Operating Income (Loss)	$-3,404.979	$-3,657.409	$-3,426.653	$-3,370.558
Net Income (Loss) Attributable to Parent	$-3,026.135	$-3,339.201	$-3,300.337	$-3,307.907
Weighted Average Number of Shares Outstanding, Basic	171,950,108	172,262,889	172,511,901	173,005,228
Research and Development Expense	$1,381.066	$1,682.55	$1,696.718	$1,699.163
General and Administrative Expense	$2,023.913	$1,974.859	$1,729.935	$1,671.395
Operating Expenses	$3,404.979	$3,657.409	$3,426.653	$3,370.558
Interest and Other Income	$378.844	$318.208	$126.316	$62.651

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Assets	$8,949.155	$5,694.658	$2,511.307	$637.19
Deferred Revenue, Noncurrent	$3,000	$3,000	$3,000	$3,000
Long-term Debt and Lease Obligation	—	—	$36.889	$21.566
Liabilities	$3,665.164	$3,709.618	$3,803.219	$3,196.46
Cash and Cash Equivalents, at Carrying Value	$8,839.912	$5,606.863	$2,375.493	$515.758
Prepaid Expense and Other Assets, Current	$109.243	$87.795	$71.507	$71.048
Assets, Current	$8,949.155	$5,694.658	$2,447	$586.806
Operating Lease, Right-of-Use Asset	—	—	$64.307	$50.384
Accounts Payable, Current	$33.731	$15.896	$51.521	$139.052
Accrued Liabilities, Current	$631.433	$693.722	$690.085	$9.58
Long-term Debt and Lease Obligation, Current	—	—	$24.724	$26.262
Liabilities, Current	$665.164	$709.618	$766.33	$174.894
Common Stock, Value, Issued	$17.202	$17.232	$17.257	$17.379
Additional Paid in Capital	$54,046.845	$54,087.065	$54,110.425	$54,143.303
Retained Earnings (Accumulated Deficit)	$-48,780.056	$-52,119.257	$-55,419.594	$-56,719.952
Stockholders' Equity Attributable to Parent	$5,283.991	$1,985.04	$-1,291.912	$-2,559.27
Common Stock, Shares Authorized	500,000,000	500,000,000	500,000,000	500,000,000
Common Stock, Shares, Issued	172,023,545	172,323,545	172,573,545	173,791,968

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-3,026.135	$-3,339.201	$-3,300.337	$-3,307.907
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-3,111.312	$-3,233.049	$-3,231.37	$-3,222.145
Net Cash Provided by (Used in) Operating Activities	$-2,700.312	$-3,233.049	$-3,231.37	$-3,222.145
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$8,839.912	$5,606.863	$2,375.493	$-655.423
Share-based Payment Arrangement, Noncash Expense	$13.784	$40.25	$23.385	$33
Increase (Decrease) in Prepaid Expenses, Other	—	—	$-16.288	$-16.288
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities	$397.382	$44.454	$28.502	$31.149

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("INTI","financials")

Full statements spill as a table. For one cell: =jivedata("INTI","Revenue") or =jivedata("INTI","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.